Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

Table 3 Surrogates of disease activity before and 3 mo after start of infliximab or adalimumab therapy, median (range)

Variable	Before start of therapy		3 mo after start of therapy		P value
	IFX	ADA	IFX	ADA	IFX	ADA
Number of bowel movements per 24 h	6 (1-30)	6 (1-17)	5 (1-40)	5 (1-20)	0.042	0.229
Occurrence of blood in stool (yes/no) (%)	32/47 (68)	23/36 (63.9)	29/50 (58)	19/35 (54.3)	0.678	0.453
CRP, (mg/L)	4.9 (0-51)	3.6 (0-122)	2.9 (0-312)	3.6 (0-145)	0.310	0.435
Leukocyte number (G/L)	9.4 (2.7-17.6)	7.7 (2.5-22)	7.4 (2.2-22.9)	7.3 (3.9-15.4)	0.037	0.524
Platelet number (G/L)	338 (150-879)	335 (194-850)	307 (166-758)	298 (170-787)	0.005	0.007
Hemoglobin (g/dL)	12.2 (8.3-15.9)	12.4 (8.1-17)	12.7 (8.5-15.9)	12.9 (6.4-16.4)	0.084	0.501

ADA: Adalimumab; IFX: Infliximab; CrP: C-reactive protein (normal: < 5 mg/L).